Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 231 to 240 of 333 total matches.

Rofecoxib for Osteoarthritis and Pain

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 1999  (Issue 1056)
of inflammation. Older NSAIDs, in varying degrees, block both COX isoforms. Rofecoxib in therapeutic doses ...
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
Med Lett Drugs Ther. 1999 Jul 2;41(1056):59-62 |  Show IntroductionHide Introduction

Zonisamide (Zonegran) For Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
— Zonisamide’s mechanism of action is unclear. It blocks sodium and calcium channels and increases dopaminergic ...
Zonisamide (Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been available in Japan for more than 10 years.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):94-5 |  Show IntroductionHide Introduction

Aripiprazole (Abilify) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003  (Issue 1150)
(Haldol, and others) and chlorpromazine (Thorazine, and others) block D 2 -dopamine receptors ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Med Lett Drugs Ther. 2003 Feb 17;45(1150):15-6 |  Show IntroductionHide Introduction

New Indications for Modafinil (Provigil)

   
The Medical Letter on Drugs and Therapeutics • Apr 26, 2004  (Issue 1181)
of the ventrolateral preoptic nucleus by blocking norepinephrine reuptake (T Gallopin et al, Sleep 2004; 27:19 ...
Modafinil (Provigil - Cephalon; Alertec - Draxis in Canada), first approved by the FDA in 1999 for treatment of excessive daytime sleepiness associated with narcolepsy (Medical Letter 1999; 41:30), has now also been approved for treatment of patients with excessive sleepiness due to obstructive sleep apnea/hypopnea syndrome (OSAHS) or shift work sleep disorder (SWSD) (DSM-IV, text revision, Washington, DC: American Psychiatric Association, 2000, page 622).
Med Lett Drugs Ther. 2004 Apr 26;46(1181):34-5 |  Show IntroductionHide Introduction

ARBs and Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • May 09, 2005  (Issue 1208)
not block breakdown of bradykinin, which is thought to be responsible for the cough associated with ACE ...
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Med Lett Drugs Ther. 2005 May 9;47(1208):38-9 |  Show IntroductionHide Introduction

Phosphate Binders

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
; 62:245. 6. GA Block et al. Effects of sevelamer and calcium on coronary artery calcification ...
Hyperphosphatemia in end-stage renal disease can lead to secondary hyperparathyroidism, renal osteodystrophy, metastatic calcification and cardiovascular mortality. addition to dietary restriction of phosphorus and hemodialysis, drugs that bind phosphates in the gut are usually needed as well. Aluminum hydroxide is no longer recommended for long-term use because of concerns about its toxicity.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):15-6 |  Show IntroductionHide Introduction

Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007  (Issue 1276)
inhibitor Mechanism of action Inhibition of mTOR kinase blocks signaling pathways involved in cell ...
Temsirolimus (Torisel - Wyeth), an mTOR (mammalian target of rapamycin) kinase inhibitor that is metabolized to sirolimus (rapamycin), has been approved by the FDA for intravenous treatment of advanced renal cell carcinoma.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):103-4 |  Show IntroductionHide Introduction

Dutasteride (Avodart) with Tamsulosin (Flomax) for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 2008  (Issue 1296)
like dutasteride block conversion of testosterone to dihydrotestosterone, which is required ...
The FDA has approved the use of the 5α-reductase inhibitor dutasteride (Avodart - GlaxoSmithKline) together with the alpha1-blocker tamsulosin (Flomax - Boehringer Ingelheim) for treatment of benign prostatic hyperplasia (BPH). Use of an alpha1-blocker with a 5α-reductase inhibitor has been a common practice for years, but FDA approval of a particular combination permits the manufacturers to add an indication for it in both package inserts, recommend dosage for combination use, and advertise the benefits of using the 2 drugs together.
Med Lett Drugs Ther. 2008 Oct 6;50(1296):79-80 |  Show IntroductionHide Introduction

Alvimopan (Entereg) for Postoperative Ileus

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
of the causes of postoperative ileus. Taken orally, alvimopan blocks the gastrointestinal (GI) effects ...
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is subcutaneously injected methylnaltrexone (Relistor), which is approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.
Med Lett Drugs Ther. 2008 Dec 1;50(1300):93-4 |  Show IntroductionHide Introduction

Tranexamic Acid (Lysteda) for Treatment of Menorrhagia

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010  (Issue 1342)
endometrial tPA activity, resulting in decreased blood loss. It blocks lysine binding sites on plasminogen ...
The FDA has approved the use of tranexamic acid (Lysteda – Ferring), an oral antifibrinolytic, for treatment of menorrhagia. Tranexamic acid has been used for this purpose in Europe for decades, and is available without a prescription in some countries. It has been available in the US since 1987 for use with coagulation factors in patients with hemophilia undergoing dental extractions.
Med Lett Drugs Ther. 2010 Jul 12;52(1342):54-5 |  Show IntroductionHide Introduction